Dual FAAH/MAGL inhibitors follow the new trend in contemporary pharmacology of multi-target-directed ligands as therapeutic compounds suitable for the treatment of complex diseases, including hypertension [38,39]. The gene discussed is FAAH; the disease is Hypertension.